Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK

Rheumatology

Volumn 43, Issue 1, 2004, Pages 62-72

  Brennan, A ^b   Bansback, N ^b   Reynolds, A ^a   Conway, P ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Anti TNF; Cost; Cost effectiveness; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; ETANERCEPT; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG COST; DRUG EFFICACY; EMPLOYMENT; FEMALE; HEALTH CARE ORGANIZATION; HEALTH STATUS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDICAL SOCIETY; MONOTHERAPY; MORTALITY; NURSING HOME; PATIENT MONITORING; PHYSICAL DISABILITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; REGRESSION ANALYSIS; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY ANALYSIS; SIDE EFFECT; SIMULATION; STATISTICAL MODEL; TREATMENT FAILURE; UNITED KINGDOM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; GREAT BRITAIN; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MODELS, ECONOMIC; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0345832266     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg451     Document Type: Article

References (62)

1. Symmons D, Turner G, Webb R et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology 2002;41:793-800.
2. Lane S, Scott D. Drug treatment of active rheumatoid arthritis. Prescriber 5 March 1999;79-95.
3. Sokka T, Hannonen P. Utility of disease modifying antirheumatic drugs in 'sawtooth' strategy. A prospective study of early rheumatoid arthritis patients up to 15 years. Ann Rheum Dis 1999;58:618-22.
4. Williams P, Young A, Cox N et al. How long do patients with early rheumatoid arthritis (RA) stay on their second line drugs? Results of a longitudinal study in 562 patients. Abstract 402, European League Against Rheumatism XIV Annual European Congress of Rheumatology, Glasgow, UK, 6-11 June 1999.
5. Galindo-Rodriguez G, Avina-Zubieta JA, Russell AS, Suarez-Almazor ME. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study. J Rheumatol 1999; 26:2337-43.
6. Young A, Dixey J, Cox N et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology 2000;39:603-11.
7. Symmons DPM, Jones MA, Scott DL, Prior P. Long term mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998;25:1072-7.
8. Goodson NJ, Wiles NJ, Lunt M et al. Mortality in early inflammatory arthritis: Cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002;46:2010-9.
9. Pincus T, Sokka T, Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum 2001;44: 1234-6.
10. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 2000;39:28-33.
11. McIntosh E. The cost of rheumatoid arthritis. Rheumatology 1996; 35:781-90.
12. Pincus T. The underestimated long term medical and economic consequences of rheumatoid arthritis. Drugs 1995;5O(Suppl. 1):1-14.
13. Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56.
14. Cooper NJ, Mugford M, Symmons DP, Barrett EM, Scott DG. Total costs and predictors of costs in individuals with early inflammatory arthritis: a community-based prospective study. Rheumatology 2000; 41:767-74.
15. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis. The impact of poor function and functional decline. Arthritis Rheum 1999;42:1209-18.
16. Moreland LW, Baumgartner SW, Schiff MH et al. Treatment of rheumatoid arthritis with recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
17. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
18. Wajdula J and the etanercept European investigators network. A double-blind, placebo-controlled study of the efficacy and safety of four different doses of etanercept in patients with rheumatoid arthritis. Abstract POS-414, European League Against Rheumatism XV Annual European Congress of Rheumatology, Nice, France, 21-24 June 2000.
19. Genovese MC, Bathon JM, Martin WM et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis. Two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46: 1443-50.
20. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
21. Anderson JA, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis. The importance of disease duration. Arthritis Rheum 2000;43:22-9.
22. New treatments in arthritis: the use of TNF-α blockers in adults with rheumatoid arthritis. Report of a working party of the British Society for Rheumatology, 2 April 2001. http://www.msecportal.org/portal/ editorial/Public Pages/bsr/536883013/l.doc
23. Lambert CM. Medical therapy for rheumatoid arthritis - value for money? Rheumatology 2001;40:961-4.
24. Geborek P, Crnkic M, Petersson IF, Mansson B, Lund TS. Efficacy of etanercept, infliximab and leflunomide in rheumatoid arthritis (RA). Experience using a clinical protocol on a regional basis. Rheumatology 2001;40(Suppl. 1):Abstract 231b, 82.
25. Tugwell P, Pincus T, Yocum D et al. The methotrexate-cyclosporine combination study group. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-14.
26. Crnkic M, Teleman A, Saxne T, Geborek P. Survival on drug as a tool for the evaluation of drug tolerability. Initial experience in southern Sweden of infliximab, etanercept and leflunomide in rheumatoid arthritis. Rheumatology 2001;40(Suppl. 1):Abstract 231b, 82.
27. Maetzel A, Bombardier C, Strand V, Tugwell P, Wells G. A metaanalysis of treatment termination rates on parenteral gold and methotrexate in rheumatoid arthritis. Arthritis Rheum 1997;40:s313.
28. Suarez-Almazor ME, Fitzgerald A, Grace M, Russel AS. A randomised controlled trial of parenteral methotrexate compared with sodium aurothiomalate (myochrysien) in the treatment of rheumatoid arthritis. J Rheumatol 1988;15:753-6.
29. Morassut P, Goldstein R, Cyr M, Karsh J, McKendry RJ. Gold sodium thiomalate compared to low dose methotrexate in the treatment of rheumatoid arthritis - a randomized, double blind 26-week trial. J Rheumatol 1989;16:302-6.
30. Munro R, Hampson R, McEntegart A, Thomson EA, Madhok R, Capell H. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Ann Rheum Dis 1998;57:88-93.
31. Smolen JS, Emery P. Efficacy and safety of leflunomide in active rheumatoid arthritis. Rheumatology 2000;39:48-56.
32. Strand V, Tugwell P, Bombardier C et al. Function and health-related quality of life: Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1870-8.
33. Emery P, Breedveld FC, Lemmel EM et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000;39:655-65.
34. Scott DL, Garrood T. Quality of life measures: use and abuse. Baillieres Clin Rheumatol 2000;14:663-87.
35. Kalden JR, Yeh P, Pedersen R, The Etanercept Study 301 Investigators. Results of ACR and DAS in patients with rheumatoid arthritis treated with etanercept (25mg twice weekly) (interim analysis). Abstract FRI0169, European League Against Rheumatism XVI Annual European Congress of Rheumatology, Stockholm, Sweden, 12-15 June.
36. Verhoeven AC, Boers M, van der Linden S. Responsiveness of the core set, response criteria and utilities in early rheumatoid arthritis. Ann Rheum Dis 2000;59:974.
37. Klareskog L, Moreland LM, Cohen S et al. Global safety and efficacy of up to five years of etanercept (Enbrel) therapy. Arthritis Rheum 2001;44:150, S77.
38. Scott DL, Pugner K, Kaarela K et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000;39:122-32.
39. Hurst N, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;336:551-9.
40. Hawthorne G, Buchbinder R, Defina J. Functional status and health-related quality of life in patients with rheumatoid arthritis. Centre for Health Program Evaluation, Monash University, December 2000. ISSN 1325 0663, ISBN 1 876662 328 (available at http://chpe.buseco. monash.edu.au/pubs/wp116.pdf 04/04/01)
41. Bansback N, Brennan A, Reynolds A, Conway P. In rheumatoid arthritis (RA) utility calculations should be derived from EQ-5D rather than SF-36 due to floor effects. Arthritis Rheum 2001; 44(Suppl.):1552, S311.
42. Monthly Index of Medical Specialities (MIMS) September 2001.
43. National Guidelines For the Monitoring of Second Line Drugs Produced by the British Society for Rheumatology July 2000 https:// www.msecportal.org/portal/editorial/PublicPages/bsr/536883013/3.doc
44. Netten A, Curtis L. Unit costs of health and social care. Personal Social Services Research Unit University of Kent, Canterbury, 2000.
45. Organisation for Economic OECD Purchasing Parity Index http://www.oecd.org/EN/links_abstract/0,,EN-links_abstract- 513-15-no-no-323-0,00.html
46. Department of Health (2000), Financial Matters May 2000, Appendix 1, Health Services Cost Index.
47. Yelin E, Trupin L, Wong B, Rush S. The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J Rheumatol 2002;29:1851-7.
48. Governments Actuary's Department - http://www.gad.gov.uk/, 12 February 2001.
49. National Institute for Clinical Excellence. Guidance for manufacturers and sponsors: Technology appraisals process series No. 5. London: National Institute for Clinical Excellence, 2001.
50. Kavanaugh A, Heudebert G, Cush J, Jain R. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model. Semin Arthritis Rheum 1996;25:297-307.
51. Verhoeven HM, Bibo JC, Boers M et al. Cost effectiveness and cost utility of combination therapy in early rheumatoid arthritis: randomised comparison of combined step down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. Rheumatology 1998; 37:1102-9.
52. Anis AH, Tugwell PX, Wells GA, Stewart DG. A cost-effectiveness analysis of cyclosporin in rheumatoid arthritis. J Rheumatol 1996; 23:609-16.
53. Choi HK, Seeger JD, Kuntz KM. A cost effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000;43:2316-27.
54. Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;42:326-35.
55. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002; 113:400-8.
56. Maini R, St Clair EW, Breedveld F et al. Infliximab versus placebo in rheumatoid arthritis receiving concomitant methotrexate: a randomised phase III trial. ATTRACT study group. Lancet 1999; 354:1932-9.
57. Jobanputra P, Barton P, Bryan S, Fry-Smith A et al. The clinical effectiveness and cost-effectiveness of new drug treatments for rheumatoid arthritis: etanercept and infliximab. http://www.nice. org.uk/pdf/RAAssessmentReport.pdf
58. Maetzel A, Tugwell P, Boers M. et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a reference case. J Rheumatol 2003;30:891-6.
59. National Institute for Clinical Excellence. Guidance on the use etanercept and infliximab for the treatment of rheumatoid arthritis, March 2002. http://www.nice.org.uk/pdf/RA-PDF.pdf
60. British Society for Rheumatology Biologics Register http://www. arc.man.ac.uk/webbiologicsreg.htm
61. Brazier J, Roberts J, Tsuchiya A. A comparison of the EQ-5D and SF-6D across seven patient groups. In: Norinder A, Pedersen KM, Roos P, eds. Proceedings of the 18th Plenary Meeting of the EuroQol, Copenhagen, 6-7 September 2001. Swedish Institute for Health Economics, 2002.
62. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Bailliere Clin Rheum 1995;9:619-32.